GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paradigm Biopharmaceuticals Ltd (OTCPK:PBIGF) » Definitions » 3-Year EPS without NRI Growth Rate

Paradigm Biopharmaceuticals (Paradigm Biopharmaceuticals) 3-Year EPS without NRI Growth Rate : -44.80% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Paradigm Biopharmaceuticals 3-Year EPS without NRI Growth Rate?

Paradigm Biopharmaceuticals's EPS without NRI for the six months ended in Dec. 2023 was $-0.11.

During the past 3 years, the average EPS without NRI Growth Rate was -44.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was -34.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 8 years, the highest 3-Year average EPS without NRI Growth Rate of Paradigm Biopharmaceuticals was -12.00% per year. The lowest was -47.00% per year. And the median was -40.30% per year.


Competitive Comparison of Paradigm Biopharmaceuticals's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Paradigm Biopharmaceuticals's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Paradigm Biopharmaceuticals's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Paradigm Biopharmaceuticals's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Paradigm Biopharmaceuticals's 3-Year EPS without NRI Growth Rate falls into.



Paradigm Biopharmaceuticals 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Paradigm Biopharmaceuticals  (OTCPK:PBIGF) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Paradigm Biopharmaceuticals 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Paradigm Biopharmaceuticals's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Paradigm Biopharmaceuticals (Paradigm Biopharmaceuticals) Business Description

Traded in Other Exchanges
Address
500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000
Paradigm Biopharmaceuticals Ltd is a biopharmaceutical company that engages in the research and development of therapeutic products for human use in Australia. The firm is engaged in drug repurposing, pentosan polysulphate sodium (PPS) for the lead clinical indication of bone marrow edema, Alphavirus - Ross River virus (RRV) and Chikungunya virus (CHIKV), Mucopolysaccharidosis, and allergic respiratory conditions, including allergic rhinitis (AR) and chronic obstructive pulmonary disease (COPD).

Paradigm Biopharmaceuticals (Paradigm Biopharmaceuticals) Headlines